<DOC>
	<DOCNO>NCT01176968</DOCNO>
	<brief_summary>Administration eplerenone within 24 hour onset symptom myocardial infarction , patient without heart failure , reduce cardiovascular mortality / morbidity .</brief_summary>
	<brief_title>Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Subjects must experience myocardial infarction ( STEMI ) within previous 24 hour confirm symptom ECG . Subjects know low ejection fraction le 40 % previous history heart failure . Subjects treat eplerenone aldosterone antagonist within past 1 month . The subject uncontrolled hypotension ( SBP &lt; 90mmHg ) . Subjects eGFR ≤30ml/min ( base admission serum creatinine MDRD formula ) serum creatinine ≥220µmol/L .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Eplerenone</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>mortality</keyword>
	<keyword>morbidity</keyword>
</DOC>